Sugarloaf Wealth Management’s Wabtec WAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
$13.3K Hold
70
﹤0.01% 458
2024
Q3
$12.7K Hold
70
﹤0.01% 473
2024
Q2
$11.1K Sell
70
-1
-1% -$160 ﹤0.01% 464
2024
Q1
$10.3K Hold
71
﹤0.01% 481
2023
Q4
$9.01K Hold
71
﹤0.01% 498
2023
Q3
$7.54K Hold
71
﹤0.01% 493
2023
Q2
$7.79K Hold
71
﹤0.01% 504
2023
Q1
$7.17K Hold
71
﹤0.01% 510
2022
Q4
$7.09K Sell
71
-8
-10% -$765 ﹤0.01% 530
2022
Q3
$7K Buy
79
+8
+11% +$707 ﹤0.01% 576
2022
Q2
$6K Hold
71
﹤0.01% 595
2022
Q1
$7K Hold
71
﹤0.01% 535
2021
Q4
$7K Hold
71
﹤0.01% 563
2021
Q3
$6K Sell
71
-3
-4% -$258 ﹤0.01% 598
2021
Q2
$6K Buy
74
+1
+1% +$81 ﹤0.01% 585
2021
Q1
$6 Sell
73
-3
-4% -$233 ﹤0.01% 577
2020
Q4
$5K Sell
76
-6
-7% -$410 ﹤0.01% 562
2020
Q3
$5K Sell
82
-52
-39% -$3.34K ﹤0.01% 531
2020
Q2
$8K Sell
134
-12
-8% -$680 ﹤0.01% 476
2020
Q1
$7K Sell
146
-65
-31% -$4.46K ﹤0.01% 482
2019
Q4
$16K Buy
+211
New +$15.6K 0.01% 405

Other funds holding WAB

Sugarloaf Wealth Management's WAB Position: Q4 2024 in Review

Sugarloaf Wealth Management held its Wabtec (WAB) position steady in Q4 2024 at 70 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #458.

Sugarloaf Wealth Management first reported a position in WAB in Q4 2019 and has held it in 21 quarters since. The position peaked at $16K in Q4 2019. 1,061 funds tracked by Wall St. Rank hold WAB as of Q4 2024.

  • Sugarloaf Wealth Management held 70 shares of Wabtec worth $13.3K as of Q4 2024.
  • Sugarloaf Wealth Management left its Wabtec share count unchanged in Q4 2024.
  • Wabtec made up ﹤0.01% of Sugarloaf Wealth Management's portfolio in Q4 2024, its #458 holding.
  • Sugarloaf Wealth Management first reported a position in Wabtec in Q4 2019 and has held it in 21 quarters since.
  • Sugarloaf Wealth Management's Wabtec position peaked at $16K in Q4 2019.
  • 1,061 funds tracked by Wall St. Rank held Wabtec as of Q4 2024.

Based on Sugarloaf Wealth Management's 13F filing for Q4 2024, filed 10 Jan 2025.